Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Intravenous Ferric Carboxymaltose (FCM) Without Erythropoiesis-stimulating Agents (ESA) in the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy With or Without Radiotherapy

NCT04246021 is registered in ClinicalTrials.gov with King Hussein Cancer Center as lead sponsor.

NCT NCT04246021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04246021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Intravenous Ferric Carboxymaltose (FCM) Without Erythropoiesis-stimulating Agents (ESA) in the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy With or Without Radiotherapy
Lead sponsor
King Hussein Cancer Center
Phase
Not applicable
Overall status
Completed
Start date
June 15, 2016
Completion date
December 31, 2017
Enrollment
84 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, cancer